H. Pylori Screening After Acute MI: HELP-MI SWEDEHEART Trial

The **HELP-MI SWEDEHEART trial** was a large, nationwide, cluster-randomized crossover study conducted across 35 hospitals in Sweden to evaluate whether routine screening for *Helicobacter pylori* (H. pylori) in patients hospitalized for acute myocardial infarction (MI) could reduce the risk of upper gastrointestinal (GI) bleeding, which is a common and serious complication after an MI.

### Key Details of the Trial:

#### 1. **Purpose and Study Design:**

• The primary aim was to determine if routine H. pylori screening and treatment in post-MI patients could lower the incidence of upper GI bleeding.
• The trial utilized a **cluster-randomized crossover design** where hospitals alternated between two approaches:
• **Routine screening periods**: Patients received urea breath testing for H. pylori in addition to standard care.
• **Usual care periods**: Patients received only standard care without screening.
• This design allowed real-world comparison of outcomes during the two periods.
• The study was open-label and conducted nationwide across 18 clusters (35 hospitals).

#### 2. **Study Population and Intervention:**

• The trial included **18,466 patients** hospitalized with acute MI, with a median age of 71 years (71% male).
• During the screening periods:
• Patients underwent **urea breath testing** to detect H. pylori infection.
• Of those tested, **23.6% tested positive for H. pylori**.
• During the nonscreening (usual care) periods, patients were treated as per standard protocols without H. pylori testing.

#### 3. **Primary Outcome: Upper GI Bleeding:**

• Over a median follow-up of **1.9 years**, the incidence of upper GI bleeding was compared between the two groups:
• **Screening group**: 299 patients experienced upper GI bleeding, corresponding to an incidence rate of **16.8 events per 1,000 person-years**.
• **Usual care group**: 336 patients experienced upper GI bleeding, corresponding to an incidence rate of **19.2 events per 1,000 person-years**.
• The **rate ratio (RR)** for upper GI bleeding was **0.90** (95% CI, 0.77–1.05; P = 0.18).
• This indicates that routine H. pylori screening did not result in a **statistically significant reduction** in the risk of upper GI bleeding.

#### 4. **Subgroup Findings and Heterogeneity:**

• Subgroup analysis revealed that the effectiveness of H. pylori screening might vary based on the presence of anemia:
• Among patients with **mild anemia**, the risk of upper GI bleeding was reduced (RR 0.64).
• Among patients with **moderate-to-severe anemia**, the reduction was even greater (RR 0.44).
• However, in patients **without anemia**, there was no benefit observed (RR 0.98).
• The **P for interaction** was 0.03, suggesting that anemia status significantly influenced the benefit of H. pylori screening.

#### 5. **Clinical Implications and Conclusion:**

• **Overall Findings**:
• Routine H. pylori screening after acute MI **did not significantly reduce the risk of upper GI bleeding** for the general post-MI population.
• **Targeted Screening Approach**:
• The subgroup analysis suggests that patients with **anemia** (especially moderate-to-severe anemia) may benefit more from H. pylori screening.
• This finding highlights the potential for a **targeted screening strategy** focusing on high-risk groups, such as anemic patients, rather than universal screening for all post-MI patients.
• **Conclusion**:
• Routine H. pylori screening is **not recommended universally** for all post-MI patients.
• A more **resource-efficient approach** could involve screening only patients at higher risk of upper GI bleeding, such as those with anemia.

The trial underscores the importance of personalized medicine, where interventions are tailored to specific patient subgroups to maximize clinical benefits and minimize unnecessary resource use.